Skip to content
Facebook Twitter Linkedin
InMed-logo-01
  • Pharmaceutical
    • Cannabinoids in Development
    • INM-755 for Epidermolysis Bullosa
    • INM-088 for Glaucoma
    • Neurodegenerative Disease
    • Novel Cannabinoid Analogs
  • Manufacturing
    • Cannabinoid Manufacturing Expertise
    • IntegraSyn™ Cannabinoid Manufacturing
    • BayMedica Cannabinoid Biosynthesis
    • Rare Cannabinoid Ingredients
  • Investors
    • News Releases
    • Events
    • Stock Information
    • Corporate Governance
    • Financials & AGM Materials
    • Filings
    • Presentations
    • Media and Videos
  • Corporate
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Partners and Collaborators
    • Careers
    • Contact
  • Learn
    • What is Cannabinol (CBN)?
    • What is Epidermolysis Bullosa (EB)?
    • What is Glaucoma?
    • Cannabinoid Manufacturing Economics 101
    • GMP Manufacturing Standards by Product Type
    • Cannabis Treatments for Glaucoma
    • Cannabinoid Science
    • Articles and Videos
Menu
  • Pharmaceutical
    • Cannabinoids in Development
    • INM-755 for Epidermolysis Bullosa
    • INM-088 for Glaucoma
    • Neurodegenerative Disease
    • Novel Cannabinoid Analogs
  • Manufacturing
    • Cannabinoid Manufacturing Expertise
    • IntegraSyn™ Cannabinoid Manufacturing
    • BayMedica Cannabinoid Biosynthesis
    • Rare Cannabinoid Ingredients
  • Investors
    • News Releases
    • Events
    • Stock Information
    • Corporate Governance
    • Financials & AGM Materials
    • Filings
    • Presentations
    • Media and Videos
  • Corporate
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Partners and Collaborators
    • Careers
    • Contact
  • Learn
    • What is Cannabinol (CBN)?
    • What is Epidermolysis Bullosa (EB)?
    • What is Glaucoma?
    • Cannabinoid Manufacturing Economics 101
    • GMP Manufacturing Standards by Product Type
    • Cannabis Treatments for Glaucoma
    • Cannabinoid Science
    • Articles and Videos

Press Releases

InMed Pharmaceuticals Announces Marketed Offering of Common Shares

April 21, 2017
Read More »

InMed Pharmaceuticals Shareholders Approve New Stock Option Plan and Articles

March 24, 2017
Read More »

InMed Pharmaceuticals to Present at the 29th Annual ROTH Conference

March 8, 2017
Read More »

InMed Pharmaceuticals Files PCT Patent for Epidermolysis Bullosa Simplex

March 2, 2017
Read More »

InMed Receives over $1,350,000 From Warrant Exercise

February 27, 2017
Read More »

InMed Pharmaceuticals to Present at the 2017 BIO CEO & Investor Conference

February 9, 2017
Read More »

InMed Pharmaceuticals, Inc. Closes Non-Brokered Private Placement for C$1,500,000

January 18, 2017
Read More »

InMed Pharmaceuticals Appoints Martin Bott to Board of Directors

January 13, 2017
Read More »

InMed Pharmaceuticals, Inc. Announces Non-Brokered Private Placement of C$1,000,000

January 9, 2017
Read More »

InMed Launches New Website

January 9, 2017
Read More »

InMed Provides 2016 Year End Update

December 23, 2016
Read More »

InMed Pharmaceuticals Announces Appointment of Veteran Biotech CFO, Jeff Charpentier

December 15, 2016
Read More »

InMed announces progress on COPD program

December 6, 2016
Read More »

InMed to Present at Cannabis-Based Therapies Conference

November 23, 2016
Read More »

InMed Pharmaceuticals, Inc. Appoints Senior Vice President, Clinical and Regulatory Affairs

October 31, 2016
Read More »

InMed Pharmaceuticals, Inc. Closes Non-Brokered Private Placement for C$1,500,000

October 27, 2016
Read More »

InMed Pharmaceuticals, Inc. Announces Non-Brokered Private Placement of C$1,500,000

October 4, 2016
Read More »

InMed Appoints Andrew Hull to the Board of Directors

September 13, 2016
Read More »

InMed to Present at 18th Annual Rodman and Renshaw Global Investment Conference

September 12, 2016
Read More »

InMed Pharmaceuticals, Inc. Closes Non-Brokered Private Placement for C$304,500

July 28, 2016
Read More »
« Previous Page1 Page2 Page3 Page4 Page5 Page6 Page7 Page8 Page9 Page10 Page11 Page12 Next »

Management

Learn More

Board of Directors

Learn More

Scientific Advisory Board

Learn More

Investor Alerts

Sign up to receive news releases from InMed Pharmaceuticals.
SIGN UP
InMed-logo-mono
#310 – 815 West Hastings St.
Vancouver, BC, Canada
V6C 1B4

Pharmaceutical

  • Cannabinoids in Development
  • INM-755 for Epidermolysis Bullosa
  • INM-088 for Glaucoma
  • Neurodegenerative Disease
  • Novel Cannabinoid Analogs

MANUFACTURING

  • Cannabinoid Manufacturing Expertise
  • IntegraSyn™ Cannabinoid Manufacturing
  • BayMedica Cannabinoid Biosynthesis
  • Rare Cannabinoid Ingredients

Investor

  • News
  • Events
  • Stock Information
  • Corporate Governance
  • Financials & AGM
  • Filings
  • Presentations
  • Media

CORPORATE

  • Management
  • Board of Directors
  • Scientific Advisory Board
  • Partners and Collaborators
  • Careers
  • Contact

Learn

  • What is Cannabinol (CBN)?
  • What is Epidermolysis Bullosa (EB)?
  • What is Glaucoma?
  • Cannabinoid Manufacturing Economics 101
  • GMP Manufacturing Standards by Product Type
  • Cannabinoids for Glaucoma
  • Cannabinoid Science
  • Articles and Videos

© Copyright 2023 InMed Pharmaceuticals Inc.

  • Privacy Policy
  • Terms of Use
  • Legal Disclaimer
  • Find Us On:
Subscribe

Sign up to receive emails from InMed Pharmaceuticals

"*" indicates required fields

Name*
Consent